AI is revolutionising healthcare strategies

In the dynamic landscape of healthcare, the continuous evolution of drug development and patient engagement necessitates ongoing innovation. Recently, GLP-1 drugs have garnered considerable attention for their revolutionary impact on treating various medical conditions, including weight loss. To explore this phenomenon further, Scott Crae, Co-Founder of Talking Medicines, hosted a session that delved into insights derived from unstructured conversational data.

Justin Wyman, Chief Revenue Officer at Socialgist, highlighted the immense potential of public online conversations aggregated by Socialgist, totalling an impressive 35 billion discussions annually. These conversations, spanning platforms from message boards to blogs and review sites, provide candid and unfiltered insights into individuals’ health perceptions and experiences, contrasting with traditional polling methods or mainstream social platforms.

Roma English Owen, Data Intelligence and Analytics Manager at Talking Medicines, explained the meticulous process of handling this vast data. Talking Medicines ensures the accuracy and relevance of the data, removing any personal identifiers. Through rigorous curation, the data is optimised for analysis, resulting in what Owen calls “curated data,” a refined dataset ready for insightful exploration.

Central to this data-driven approach is Drug-GPT, a proprietary AI model developed by Talking Medicines. By processing curated data, Drug-GPT provides healthcare professionals with actionable intelligence from unstructured conversational data, enhancing productivity and return on investment. Its user-friendly natural language interface eliminates training barriers, making invaluable insights accessible and fostering more effective strategies.

The session underscored the significant potential of combining advanced AI technologies with unstructured conversational data to shape the future of healthcare. By understanding the intricacies of healthcare discourse surrounding GLP-1 drugs and other advancements, stakeholders can navigate the complex healthcare landscape with greater confidence and efficacy. Drug-GPT captures the lived experiences of the GLP-1 drugs revolution, supporting data-driven decision-making and ushering in a new era of informed healthcare strategies.

In conclusion, the discussion highlighted the transformative power of analysing unstructured conversational data in healthcare, particularly regarding GLP-1 drugs. By leveraging advanced AI models like Drug-GPT and curated data from platforms like Socialgist, stakeholders gain invaluable insights, driving productivity and informed healthcare strategies. For strategists seeking clarity amidst complexity, Drug-GPT is more than a tool; it is an essential partner in transforming healthcare marketing strategies into informed, data-driven powerhouses.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. The Talking Medicines mission is to be the World’s Gold Standard for Patient Intelligence by Medicine.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Tern plc

More articles like this

Tern plc

Maximising ROI in healthcare marketing with advanced AI solutions

In healthcare marketing, reaching the right audience—whether patients or healthcare providers (HCPs)—is more important than ever. Traditional marketing methods often fail to deliver the nuanced insights necessary for effective messaging. This is where artificial intelligence (AI)

Tern plc

AI in healthcare and the importance of ethical governance

Artificial intelligence is quickly transforming industries, bringing innovation and reshaping business practices. However, with its rapid growth comes a need for responsible oversight to ensure AI is used ethically and responsibly. AI’s adoption poses distinct challenges

Tern plc

Understanding Privileged Access Management and its role in cybersecurity

Privileged Access Management (PAM) is an essential approach to safeguarding privileged accounts—those with elevated permissions enabling high-level actions within an organisation’s IT systems. These accounts provide access to sensitive data and critical systems, making them prime

Tern plc

Emerging trends in IoT shaping industry with AI integration

The Internet of Things (IoT) has expanded rapidly, with connected devices influencing many aspects of our lives. This interconnected landscape is set to grow even further, with global investment in IoT anticipated to surpass $1 trillion

Tern plc

Transforming Ophthalmic education with VR training

The American Academy of Ophthalmology, in collaboration with the immersive training company FundamentalVR, has introduced a new initiative, the Academy’s VR Education program. This programme aims to revolutionise ophthalmic education and surgical training through the use

Tern plc

Strengthening cybersecurity compliance: Understanding the impact of NIS2

As digital transformation accelerates, cybersecurity risks grow in parallel, particularly for organisations managing critical infrastructure and sensitive data. The European Union (EU) has responded to these emerging challenges by updating its cybersecurity regulations with NIS2 (Network

Tern plc

Device Authority’s KeyScaler as a Service reaches major milestone

Device Authority has recently surpassed a significant milestone with its cloud-native platform, KeyScaler as a Service (KSaaS), now managing over 11 million machine identity authentications across 49 countries. This achievement showcases the rising demand for scalable

Tern plc

Revolutionising surgical training with immersive technology

The field of medical training is constantly evolving, yet ensuring competency on a large scale remains a consistent challenge. As the need for skilled surgeons and healthcare workers grows, traditional approaches—using cadavers, simulations, and hands-on experience

Tern plc

Tern raises £625,000 via Placing

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that it has raised £625,000, before expenses, through a placing of 50,000,000 new ordinary shares of 0.02p each

Tern plc

Strengthening IoT and OT security through strategic partnerships

The rapid growth of Internet of Things (IoT) and Operational Technology (OT) devices has revolutionised industries, enhancing innovation, efficiency, and automation. However, with the increasing adoption of these devices, security challenges have become more pronounced. Traditional

Tern plc

The future of surgical training lies in virtual reality

Surgical advancements over the past century have been remarkable, yet the reality remains that more than 5 billion people globally lack access to safe surgical procedures. This is largely due to a shortage of trained surgeons.

Tern plc

Empowering rare disease communities through AI

Rare disease communities encounter a range of challenges that go far beyond just patient care, many of which are frequently overlooked in broader health strategies. With more than 7,000 rare diseases affecting relatively small and diverse

Tern plc

How IoT automation is transforming industry

The integration of the Internet of Things (IoT) is reshaping the way industries operate, particularly through innovations like smart manufacturing, predictive maintenance, and remote monitoring. With these advancements, industries can streamline processes, improve productivity, and enhance